Detrusor overactivity threatens the renal function of patients with spinal cord injury. Suppressing N-methyl-D-aspartate receptors is known to improve detrusor overactivity in rats with spinal cord injury, whereas kynurenic acid, the endogenous antagonist of N-methyl-D-aspartate receptors, is irreversibly synthesized by kynurenine aminotransferases (KATs). In this study, we investigated whether replication-defective herpes simplex virus vector-mediated gene transfer of human KAT II could treat detrusor overactivity by injecting the vectors into the rat bladder wall 1 week after spinal cord injury. Three weeks after injection, we evaluated the cystometry and gene expression of KAT II in L6-S1 dorsal root ganglia. The results showed that the vectors are transported to L6-S1 dorsal root ganglia and upregulate the expression of KAT II, and that they also improve the detrusor overactivity and voiding efficiency. We also proved that N-methyl-D-aspartate receptors were blocked by kynurenic acid in the extracellular solution or the vector-mediated gene transfer of KAT II in cultured rat neurons of L6-S1 dorsal root ganglia by whole-cell patch clamp to explore the mechanisms of gene therapy. Therefore, replication-defective herpes simplex virus vector-mediated KAT II inhibits detrusor overactivity in spinal cord-injured rats, possibly by suppressing N-methyl-D-aspartate receptors in bladder afferent pathways.
INTRODUCTION
Detrusor overactivity (DO) and detrusor-sphincter dyssynergia (DSD) caused by spinal cord injury (SCI) usually lead to a thickwalled bladder with low compliance and elevated pressures, hydronephrosis and kidney dysfunction. 1, 2 The glutamatergic system, via N-methyl-D-aspartate receptor (NMDAR) activation, has an important role in the control of micturition. MK-801, a potent non-competitive NMDAR antagonist, reportedly increases bladder capacity, reduces bladder contractions, 3 inhibits external urethral sphincter contractions and increases maximum flow rate 4, 5 in SCI rats. These results suggest that blocking NMDARs could improve SCI-induced DO and DSD.
Kynurenic acid (KYNA), the only known endogenous antagonist of glutamate receptors, is able to block NMDARs. 6, 7 A study showed that KYNA intrathecal application to the sacral cord completely inhibits bladder contractions in cats. 8 In the rat and human brain, over 70% of KYNA is formed from L-kynurenine catalyzed by kynurenine aminotransferase II (KAT II). 9, 10 Human KAT II cDNA is about 1.5 kb, encoding a mitochondrial protein of 425 amino residues (NP_057312). Thus, gene delivery of KAT II that increases KYNA, suppressing NMDAR-mediated action in micturition, could be a useful approach for the treatment of SCI-induced DO and DSD.
Research using replication-defective herpes simplex virus vectors (HSVrds) to treat neuropathies and pain imply that they could have a bright future in the treatment of bladder dysfunction. 11 HSVrd vectors are non-toxic, neurotropic gene transfer tools that could express therapeutic genes after latent infections in the dorsal root ganglia (DRG). 12 These characteristics guarantee that the vectors will deliver the KAT II gene to targeted afferent pathways after bladder-wall injection, with limited side effects, in the treatment of SCI-induced neurogenic bladder. Previous reports showed that HSVrd-mediated gene transfer of glutamic acid decarboxylase, the enzyme that synthesizes γ-aminobutyric acid, delivered through bladder-wall inoculation, can reduce DO and DSD in SCI rats. 13, 14 Therefore, in this study, we tested the hypothesis that HSVrdmediated gene transfer of KAT II could improve DO in SCI rats. Specifically, we injected HSVrd vectors encoding KAT II (HSVrd-KAT II) into the bladder wall of male rats 1 week after T 10 spinal cord transection and evaluated their effects on cystometrograms and KAT II gene expression in L6-S1 DRG 3 weeks after viral inoculation. To explore the mechanisms of this gene therapy, we also evaluated whether NMDARs were blocked after the gene transfer of KAT II by HSVrd vectors in cultured rat L6-S1 DRG neurons using whole-cell patch clamp.
RESULTS
Conscious cystometry (n = 16 each group) One week after complete transection of the T 10 spinal cord in male rats, normal saline (sham group; n = 16), HSVrd control vector (HSVrd group; n = 16) or HSVrd-KAT II (HSVrd-KAT II group; n = 16) was injected into the rat bladder wall. Three weeks after injection, the cystometry and gene expression of KAT II in L6-S1 DRG were evaluated. Representative traces of cystometry in three groups are shown in Figure 1 . In the sham and HSVrd groups, all rats showed high amplitudes of non-voiding bladder contractions (NVCs) before fluid leaks from the urethra. There were no significant differences in cystometric parameters between the sham and HSVrd groups (Table 1) . However, the number and amplitude of NVCs, maximum voiding pressure and volume thresholds inducing voiding were decreased significantly by 59.6-61.1%, 21.6-24.2%, 30.3-34.4% and 44.1-46.5% (P o0.01), and voiding efficiency and time to first NVC were increased significantly by 40.7-47.7% and 30.1-49.0% (P o 0.01), respectively, in the HSVrd-KAT II group compared with the sham or HSVrd groups (Table 1) .
Immunofluorescent staining in HSVrd and HSVrd-KAT II groups (n = 4 each) Viral positive neurons shown by red fluorescent protein (RFP) immunoreactivity were found in 37.2 ± 8.6% (HSVrd group) and 39.6 ± 5.7% (HSVrd-KAT II group) of neuronal profiles in DRG sections. The KAT II-positive neurons in DRG were significantly increased from 8.1 ± 4.6% of DRG neuronal profiles in the HSVrd group to 32.4 ± 7.2% in the HSVrd-KAT II group (P o0.01) (Figure 2 ).
Comparison of KAT II protein levels in HSVrd and HSVrd-KAT II groups (n = 4 each) The ratio of KAT II/glyceraldehyde 3-phosphate dehydrogenase proteins, which was used to assess KAT II expression in L6-S1 DRG using western blot analysis, was significantly increased by 78.6% in the HSVrd-KAT II group (0.50 ± 0.13) compared with the HSVrd group (0.28 ± 0.07) (P o 0.05) (Figure 3a) .
Comparison of KAT II mRNA level in HSVrd and HSVrd-KAT II groups (n = 4 each)
The ratio of KAT II/β-actin mRNA, which was used to assess KAT II mRNA expression in L6-S1 DRG using quantitative real-time polymerase chain reaction, was significantly increased by 52.9% in the HSVrd-KAT II group (0.78 ± 0.06) compared with the HSVrd group (0.51 ± 0.08) (Po 0.01) (Figure 3b ).
Effect of KYNA or KAT II gene transfer on NMDAR currents The amplitude of NMDAR currents in vector-untreated rat L6-S1 DRG neurons significantly decreased by 75.6% after KYNA (1 mM) incubation compared with two-related-sample Wilcoxon tests (n = 10, P o 0.01) ( Figure 4A ), whereas it significantly decreased by 56.7% in HSVrd-KAT II-treated neurons (n = 11) over HSVrd-treated neurons (n = 17) compared with Mann-Whitney U-tests (P o0.05) ( Figure 4B ).
DISCUSSION
This study indicated that bladder-wall injection of HSVrd-KAT II in rats with T 10 spinal cord transection: (1) improves DO, as shown by the reductions in NVC number and amplitudes and prolongation of the time to first NVC and (2) improves voiding efficiency with reduced maximum voiding pressure, probably due to the suppression of DSD.
Two types of afferent fibers, namely Aδ and C fibers, are well known to carry sensory information from the bladder to the spinal cord. 15, 16 In cats and rats, Aδ-fiber bladder afferents trigger normal micturition via a long-latency supraspinal pathway passing through the pons. 15, 17 In SCI rats, C-fiber afferents appear to initiate DO, although Aδ-fiber bladder afferents still trigger the voiding reflex, 15, 17 because desensitizing C-fiber afferents by systemic capsaicin administration suppressed NVCs in SCI rats. 18 This capsaicin effect is similar to that seen in the current experiment (i.e., reduced NVCs) following KAT II gene therapy in SCI rats, suggesting that HSVrd-KAT II therapy inhibits DO by suppressing C-fiber bladder afferents whose activity is enhanced in the SCI condition.
Previous studies also indicated that hyperexcitability of C-fiber bladder afferents is involved in DSD after SCI, because C-fiber desensitization by capsaicin pretreatment reduces urethral contraction pressure during bladder contraction in SCI rats. 19 In this study, although the urethral pressure change during bladder contractions was not directly evaluated, voiding efficiency was increased along with decreased maximum voiding pressure in HSVrd-KAT II-treated SCI rats, suggesting that HSVrd-mediated KAT II gene delivery reduces urethral resistance during voiding, resulting in improved voiding efficiency. In addition, the inhibition of external urethral sphincter contraction during bladder contractions may contribute to the significant decrease of volume thresholds inducing voiding after HSVrd-KAT II injection, because low urethral resistance can induce earlier voiding at a lower bladder pressure. Overall, suppression of C-fiber bladder afferent activity after HSVrd-mediated KAT II gene delivery might also inhibit DSD in SCI rats, although further studies are needed to confirm this point.
To test our hypothesis that HSVrd-KAT II therapy inhibits DO by suppressing C-fiber bladder afferents in SCI rats, we examined the effects of exogenous application of KYNA or KAT II gene delivery on NMDAR currents in rat cultured L6-S1 DRG neurons using whole-cell patch-clamp techniques. NMDARs reportedly have an important role in the control of micturition, because inhibiting NMDARs can improve DO and DSD in SCI rats. [3] [4] [5] KYNA, one of the final products formed by KAT II-mediated catalysis, is an endogenous antagonist of NMDARs in the brain. 6, 7 We found (c) The membrane current amplitude induced by NMDA (1mM) was significantly decreased in HSVrd-KAT II-treated neurons (n = 11) compared with HSVrd-treated neurons (n = 17). *P o0.05, compared using Mann-Whitney U-tests. Holding membrane potential: − 70mV.
that KYNA applied to the extracellular solution blocks NMDAinduced inward currents in small-to medium-sized, dissociated DRG neurons. Previous reports showed that newly formed KYNA could quickly release into the extracellular milieu, 20 suggesting that increased KYNA after KAT II gene delivery to DRG neurons could release KYNA to the outside of the same or neighboring neurons to suppress afferent neuron activity by blocking NMDARs. KYNA not only increases extracellularly but also intracellularly after KAT II gene delivery, in theory; therefore, we also tested the activity of NMDARs after HSVrd-mediated KAT II gene delivery and found that NMDA-induced inward currents were reduced in cultured DRG neurons transfected with HSVrd-KAT II for 48-72 h in the culture medium. These results suggest that intracellularly increased KYNA can suppress NMDAR activity of DRG neurons. In this study, KAT II expression in L6-S1 DRG was upregulated after HSVrd-KAT II treatment. Thus, it is reasonable to assume that HSVrd-mediated KAT II gene delivery is efficient in treating neurogenic DO in SCI rats through suppression of bladder afferent activity by blocking NMDARs. However, further studies are needed to verify this assumption, because patchclamp studies in this study were performed on nonspecific DRG neurons rather than identified C-fiber bladder afferent neurons.
Glutamate released from primary afferents is a major excitatory neurotransmitter that conveys nociceptive information to the spinal cord dorsal horn neurons. 21, 22 Previous studies showed that bladder-wall injection of HSVrd vectors encoding glutamic acid decarboxylase, the synthetizing enzyme of γ-aminobutyric acid, suppressed DO and DSD in SCI rats via stimulation of inhibitory γ-aminobutyric acid receptors in the spinal cord. 13, 14 Therefore, this study also suggests that HSVrd-KAT II injected into the bladder wall are transported through bladder afferent pathways not only to produce KYNA in the DRG neurons to suppress afferent activity but also to release KYNA into the spinal cord, thereby suppressing NMDAR-mediated excitation of the micturition reflex in the spinal cord.
Therefore, this study found that HSVrd-KAT II vectors injected into the bladder wall are transported to L6-S1 DRG, which contain bladder afferent neurons and improve DO and voiding efficiency in SCI rats, possibly due to NMDAR blockade in the DRG and spinal cord.
MATERIALS AND METHODS

Viral vectors
The HSVrd-KAT II vector was constructed by recombining the RG223277 plasmid (Origene Technologies, Beijing, China) human KAT II cDNA into the ICP4, ICP27 and ICP34.5 deleted HSVrd vector (SinoGenoMax Co., Beijing, China) with 6-His tag derived from wild HSV-I virus ( Figure 5 ). Both HSVrd and HSVrd-KAT II express the viral reporter protein RFP under the control of an EF1a promoter. The vectors were propagated in the OG01 cell line (SinoGenoMax Co.) derived from a Vero cell (CCL-81; ATCC, Manassas, VA, USA) that supplies ICP4 and ICP27 in trans.
Animal preparation and viral administration
Forty-eight male Sprague-Dawley rats (Academy of Military Medical Sciences, Beijing, China) weighing 240-280 g were spinalized with complete transection of the T 10 spinal cord under 2% isoflurane anesthesia according to the experimental protocol approved by the ethics committee of the China Rehabilitation Research Center. Postoperatively, the rats were treated with ampicillin (100 mg kg − 1 intramuscularly) for 3 days. The bladder of spinalized rats was expressed manually three times daily until the reflex voiding was recovered (9-14 days), and then once daily.
One week after spinalization, rats were randomly assigned to one of three groups and received a bladder-wall injection under 2.0% isoflurane anesthesia: (1) with normal saline (sham; n = 16); (2) with HSVrd control vector (HSVrd; n = 16) and (3) with HSVrd-KAT II (HSVrd-KAT II; n = 16). After exposure of the rat bladder via midline abdominal incision, a total of 40 μl normal saline, viral suspension of HSVrd or HSVrd-KAT II (1 × 10 7 plaqueforming units) was injected into four sites around the bladder base and four sites around the middle of the bladder wall using a 30-G syringe (10 μl; Hamilton Co., Reno, NV, USA). After the abdomen was closed, the rats received ampicillin (100 mgkg − 1 intramuscularly) for 3 days.
Cystometry in conscious spinalized rats (n = 16 for each group)
Three weeks after bladder injection, the rat bladder dome was exposed via a midline abdominal incision, and the ureters were ligated at the level of the aortic bifurcation under 2% isoflurane anesthesia. The bladder was emptied, and a PE-50 catheter was inserted from the bladder dome to record intravesical pressure. The intravesical catheter was connected to an a PT 100 Pressure Transducer (Chengdu Technology & Market Co., Sichuan, China) for pressure monitoring and to a WZ-50C66T microinfusion pump (Smiths Medical Instrument Co., Zhejiang, China) for bladder infusion through a three-way stopcock. After the abdomen was closed, the rats were allowed to recover from anesthesia for 1 or 2 h, and then normal saline at room temperature was infused into the bladder at 0.08 ml min − 1 . Once fluid was released from the urethra, the infusion was stopped, and the residual volume was measured. The data were recorded and analyzed using the BL-420F software (Chengdu Technology & Market Co.). Cystometric parameters were recorded after at least two stable micturition cycles.
The number and amplitude of all NVCs, maximum voiding pressure (cm H 2 O), and volume thresholds inducing voiding (ml), time to first NVC (min), voided volume (ml) and voiding efficiency (%) were measured. NVCs were defined as rhythmic intravesical pressure increases >7 cm H 2 O from baseline pressure without the release of fluid from the urethra. 13 Immunofluorescent staining in HSVrd and HSVrd-KAT II groups (n = 4 each) After cystometry, rats were perfused with 4% paraformaldehyde, and L6-S1 DRGs were removed. Cryostat sections (10 μm) of DRG were mounted onto poly-L-lysine-coated slides. Primary antibodies of rabbit anti-human KAT II (H-301) antibody, mouse anti-DsRed (N9) antibody (1:200; Santa Cruz Biotechnology, Santa Cruz, CA, USA), and secondary antibodies of goat anti-rabbit immunoglobulin G-conjugated tetramethylrhodamine, Alexa Fluor 488-conjugated rabbit anti-mouse immunoglobulin G (1:200; Invitrogen, Carlsbad, CA, USA), were used for the detection of KAT II and RFP. A negative control was prepared without primary antibody. In randomly selected DRG sections (n = 3 sections per animal), the intensity of RFP or KAT II immunoreactivity was rated on a four-point scale (0-3), and the neurons that exhibited grade 2 or 3 were regarded as positively stained cells. The ratio of positively stained cells to total DRG cells per section was calculated.
Western blot quantification of KAT II protein in HSVrd and HSVrd-KAT II groups (n = 4 each) L6-S1 DRG were homogenized with RIPA buffer (Sigma-Aldrich, Shanghai, China) containing protease inhibitor cocktail (Sigma-Aldrich) and centrifuged at 10 000 r.p.m. for 10 min at 4°C. Thirty μg protein in the supernatant was separated in a 12% Tris-HCl polyacrylamide gel (Bio-Rad Laboratories Inc., Beijing, China), transferred onto a nitrocellulose membrane (Bio-Rad Laboratories Inc.), incubated with rabbit anti-human KAT II (H-301) antibody and glyceraldehyde 3-phosphate dehydrogenase protein (H-12) monoclonal antibody (1:500 and 1:1000, respectively; Santa Cruz Biotechnology) for 2 h at room temperature, followed by horse radish peroxidase-conjugated goat anti-rabbit antibody and horse radish peroxidase-conjugated goat anti-mouse antibody (1:5000; Santa Cruz Biotechnology) for 1 h at room temperature. The intensity of each band was determined by VersaDoc image acquisition and analysis software (Bio-Rad laboratories Inc.). The ratio of KAT II/glyceraldehyde 3-phosphate dehydrogenase protein was calculated.
Quantification of KAT II mRNA in HSVrd and HSVrd-KAT II groups (n = 4 each) Total RNA was extracted from L6-S1 DRG using TRIzol reagent (Invitrogen) and reverse transcribed into cDNA using the TIANScript RT Reagent kit (Tiangen Biotech, Beijing, China). KAT II levels were examined with quantitative real-time polymerase chain reaction with TIANScript RT Reagent Kit (Tiangen Biotech) and SYBR Premix Ex Taq II (Invitrogen) using a TL988 II System (Tianlong, Xian, China). Primers for KAT II (forward primer: 5′-TAGTAACCAGAAGGATGCAA-3′; reverse primer: 5′-GCTGAA GAGAAGGATGCTC-′) and β-actin (forward primer: 5′-ACACCCGCC ACCAGTTC-3′; reverse primer: 5′-TGACCCATACCCACCATC-3′) were used. Amplification of cDNA was performed as follows: 95°C for 2 min, and then 45 cycles of 94°C for 30 s, 54°C for 30 s and 72°C for 30 s. The reaction system was as follows: SYBR Premix Ex Taq II 1 μl, 10 × polymerase chain reaction buffer 2.5 μl, dUTP 0.5 μl, each primer 0.5 μl, cDNA 2 μl and Taq DNA polymerase 0.5 μl, with RNase-free ddH 2 O added up to 25 μl. Each sample was tested three times, and melting-curve analysis was performed to confirm primer specificity. Standard curves were constructed from serial dilution of cDNA in each tissue, and quantification of the samples was achieved using the standard curve. The ratio of KAT II/β-actin mRNA was compared between the two groups.
Isolation and primary culture of DRG neurons
The experiments were performed on female Sprague-Dawley rats (100-140 g; Hilltop Animal Care, Pittsburgh, PA, USA) in accordance with the requirements and recommendations in the Guide for the Care and Use of Laboratory Animals (Institute for Laboratory Animal Research, 1985) approved by the University of Pittsburgh (Pittsburgh, PA, USA) Institutional Animal Care and Use Committee. Under 2.0% isoflurane anesthesia, a low dorsal midline incision was performed to remove quickly the L6-S1 DRG. The DRGs were minced, placed in medium consisting of 4.5 ml Neurobasal-A medium (Invitrogen), 5 μl 5% B27 supplements (Invitrogen), 45 μl 1% penicillin-streptomycin-neomycin solution (Sigma-Aldrich), 0.45 ml fetal bovine serum (Invitrogen), 5 mg trypsin (Worthingtown Biochemical, Lakewood, NJ, USA), and 10 mg collagenase type 4 (Worthingtown Biochemical), and incubated at 37°C for 20-30 min. After trituration using a pipette, the cell suspension was centrifuged for 5 min at 416 g. The cell pellet was then resuspended in the medium described above without trypsin and collagenase type 4. Neurons were plated on poly-L-lysine-coated 35-mm culture dishes and cultured at 37°C in a 5% CO 2 incubator. Vector-untreated neurons were studied after 24-72 h in culture. HSVrd or HSVrd-KAT II-treated neurons (multiplicity of infection: 1:10) were studied after 48-72 h transinfection.
Electrophysiological recordings
Whole-cell patch-clamp recordings were performed with a Multiclamp 700A amplifier, Dididata 1322A analog-to-digital converter interface (Axon Instruments, Foster City, CA, USA), and pCLAMP 8. Drug delivery for patch clamp NMDA (Tocris Cookson Inc., Ellisville, MO, USA) and KYNA (Sigma-Aldrich) were prepared as 5 mM stock solutions containing 0.25% dimethylsulfoxide and diluted daily into a 1 mM concentration in the extracellular solution. We confirmed that application of the 0.05% dimethylsulfoxide-containing extracellular solution without test compounds did not induce membrane currents. The extracellular solution containing test compounds was rapidly perfused onto the patched cells using a gravity-fed multibarrel perfusion system (SF-77B Perfusion Fast-Step; Warner Instruments, Hamden, CT, USA) controlled with a Labmaster board using pCLAMP 8.2 software (Axon Instruments). The tip of the multibarrel was positioned 200-300 μm from the neuron during recording. The agonist NMDA was applied to the neurons for 2 min to induce inward currents and, after washing with extracellular solution containing 0.05% dimethylsulfoxide and 1 mM KYNA for 4 min, NMDA was given again to record NMDA-induced inward currents after KYNA incubation.
Statistical analysis
Data are expressed as mean ± s.e. One-way analysis of variance, two-related-sample Wilcoxon tests, Mann-Whitney U-tests or independent t-tests were used, with P o 0.05 considered statistically significant.
